Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

Lenalidomide has been linked to second primary malignancies in myeloma. We aimed to pool and analyse available data to compare the incidence of second primary malignancies in patients with and without lenalidomide exposure. We identified relevant studies through a search of PubMed and abstracts from...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The lancet oncology Jg. 15; H. 3; S. 333 - 342
Hauptverfasser:	Palumbo, Antonio, Bringhen, Sara, Kumar, Shaji K, Lupparelli, Giulia, Usmani, Saad, Waage, Anders, Larocca, Alessandra, van der Holt, Bronno, Musto, Pellegrino, Offidani, Massimo, Petrucci, Maria T, Evangelista, Andrea, Zweegman, Sonja, Nooka, Ajay K, Spencer, Andrew, Dimopoulos, Meletios A, Hajek, Roman, Cavo, Michele, Richardson, Paul, Lonial, Sagar, Ciccone, Giovannino, Boccadoro, Mario, Anderson, Kenneth, Barlogie, Bart, Sonneveld, Pieter, McCarthy, Philip L
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Elsevier Ltd 01.03.2014 Elsevier Limited
Schlagworte:	Age Angiogenesis Inhibitors - adverse effects Bone marrow Hematology Hematology, Oncology and Palliative Medicine Humans Melphalan - adverse effects Meta-analysis Multiple Myeloma - drug therapy Multivariate analysis Neoplasms, Second Primary - chemically induced Patients Thalidomide - adverse effects Thalidomide - analogs & derivatives Transplants & implants
ISSN:	1470-2045, 1474-5488, 1474-5488
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!